BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 1309066)

  • 1. Bispecific monoclonal antibodies increase the fibrin-specific fibrinolytic activity of tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA).
    Bos R; Nieuwenhuizen W
    Ann N Y Acad Sci; 1992 Dec; 667():428-30. PubMed ID: 1309066
    [No Abstract]   [Full Text] [Related]  

  • 2. Plasma tissue-type plasminogen activator increases fibrinolytic activity of exogenous urokinase-type plasminogen activator.
    Shenkman B; Livnat T; Budnik I; Tamarin I; Einav Y; Martinowitz U
    Blood Coagul Fibrinolysis; 2012 Dec; 23(8):729-33. PubMed ID: 22918041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific monoclonal antibodies produced by somatic cell fusion increase the potency of tissue plasminogen activator.
    Branscomb EE; Runge MS; Savard CE; Adams KM; Matsueda GR; Haber E
    Thromb Haemost; 1990 Oct; 64(2):260-6. PubMed ID: 2125375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conjugation to an antifibrin monoclonal antibody enhances the fibrinolytic potency of tissue plasminogen activator in vitro.
    Runge MS; Bode C; Matsueda GR; Haber E
    Biochemistry; 1988 Feb; 27(4):1153-7. PubMed ID: 3130094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of fibrin specificity in therapeutic thrombolysis and the rationale of using sequential and synergistic combinations of tissue plasminogen activator and pro-urokinase.
    Gurewich V
    Semin Thromb Hemost; 1989 Apr; 15(2):123-8. PubMed ID: 2501871
    [No Abstract]   [Full Text] [Related]  

  • 6. Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy.
    Collen D
    Prog Hemost Thromb; 1986; 8():1-18. PubMed ID: 3104986
    [No Abstract]   [Full Text] [Related]  

  • 7. Antibody-directed fibrinolysis. An antibody specific for both fibrin and tissue plasminogen activator.
    Bode C; Runge MS; Branscomb EE; Newell JB; Matsueda GR; Haber E
    J Biol Chem; 1989 Jan; 264(2):944-8. PubMed ID: 2492021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of fibrinolysis by bispecific monoclonal antibodies reactive to fibrin and plasminogen activators.
    Kurokawa T; Iwasa S; Kakinuma A
    Thromb Res Suppl; 1990; 10():83-9. PubMed ID: 2107601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI.
    Mutch NJ; Moore NR; Wang E; Booth NA
    J Thromb Haemost; 2003 Sep; 1(9):2000-7. PubMed ID: 12941043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
    Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
    Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Thrombolysis using tissue-type plasminogen activator and pro-urokinase: synergism; mutants and hybrids].
    Páramo JA; Fernández FJ; Cuesta B; Paloma MJ; Rocha E
    Sangre (Barc); 1989 Aug; 34(4):297-9. PubMed ID: 2505395
    [No Abstract]   [Full Text] [Related]  

  • 12. Recombinant human C1-inhibitor prevents non-specific proteolysis by mutant pro-urokinase during optimal fibrinolysis.
    Gurewich V; Pannell R
    Thromb Haemost; 2009 Aug; 102(2):279-86. PubMed ID: 19652878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A hybrid molecule of pro-urokinase and a fibrin-specific, monoclonal antibody fragment is a more effective thrombolytic agent than pro-urokinase in vitro and in vivo].
    Bode C; Eberle T; Runge M; Haber E; Kübler W
    Verh Dtsch Ges Inn Med; 1990; 96():1-3. PubMed ID: 2128723
    [No Abstract]   [Full Text] [Related]  

  • 14. Antibody-directed fibrinolysis: a bispecific (Fab')2 that binds to fibrin and tissue plasminogen activator.
    Runge MS; Bode C; Savard CE; Matsueda GR; Haber E
    Bioconjug Chem; 1990; 1(4):274-7. PubMed ID: 2129015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.
    Wu JH; Diamond SL
    J Clin Invest; 1995 Jun; 95(6):2483-90. PubMed ID: 7769094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cleavage of surfactant-incorporating fibrin by different fibrinolytic agents. Kinetics of lysis and rescue of surface activity.
    Günther A; Markart P; Kalinowski M; Ruppert C; Grimminger F; Seeger W
    Am J Respir Cell Mol Biol; 1999 Dec; 21(6):738-45. PubMed ID: 10572071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator.
    Bugge TH; Flick MJ; Danton MJ; Daugherty CC; Romer J; Dano K; Carmeliet P; Collen D; Degen JL
    Proc Natl Acad Sci U S A; 1996 Jun; 93(12):5899-904. PubMed ID: 8650190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endothelium and disordered fibrin turnover in the injured lung: newly recognized pathways.
    Idell S
    Crit Care Med; 2002 May; 30(5 Suppl):S274-80. PubMed ID: 12004248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of intrapleural fibrinolysis by urokinase-alpha-macroglobulin complexes in tetracycline-induced pleural injury in rabbits.
    Komissarov AA; Mazar AP; Koenig K; Kurdowska AK; Idell S
    Am J Physiol Lung Cell Mol Physiol; 2009 Oct; 297(4):L568-77. PubMed ID: 19666776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in the activation rates of plasminogen by tissue plasminogen activator and urokinase.
    Takada A; Shizume K; Cho M; Takada Y
    Thromb Res; 1987 Feb; 45(4):371-81. PubMed ID: 2437668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.